Intravitreal Ranibizumab versus Razumab in treatment naïve diabetic macular edema

Dhandapani A, Ravindran S, Muthusamy K, Muruganandham K, Kaliamurty S

Pdf Page Numbers :- 201-205

Archana Dhandapani¹, Saravanan Ravindran¹, Kannan Muthusamy¹, Kavitha Muruganandham¹ and Suresh Kaliamurty^1,*

¹Department of Ophthalmology, Southern Railway Headquarters Hospital, Ayanavaram, Chennai- 600023, India

*Corresponding author: Dr. Suresh K, Head of Department and Additional Chief Health Director, Department of Ophthalmology, Southern Railway Headquarters Hospital, Ayanavaram, Chennai- 600023, India. Email: sursophthal@gmail.com

Received 4 January 2025; Revised 25 February 2025; Accepted 6 March 2025; Published 17 March 2025

Citation: Dhandapani A, Ravindran S, Muthusamy K, Muruganandham K, Kaliamurty S. Intravitreal Ranibizumab versus Razumab in treatment naïve diabetic macular edema. J Med Sci Res. 2025; 13(2):201-205. DOI: http://dx.doi.org/10.17727/JMSR.2024/13-35

Copyright: © 2025 Dhandapani A et al. Published by KIMS Foundation and Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PDF

Abstract

Background: Diabetic macular edema (DME) is a leading cause of vision impairment globally among working population, with anti-vascular endothelial growth factor (anti-VEGF) therapies being the standard treatment. The high cost of anti-VEGF drive use of biosimilars like Razumab®. This study provides a prospective real-world comparison of innovator ranibizumab and Razumab® in treatment-naïve DME patients, addressing the current gap in comparative data.

Methods: A prospective observational study was conducted involving 60 treatment-naïve DME patients, equally divided into two groups: Ranibizumab and Razumab®. Each group received three intravitreal injections at monthly intervals. Best corrected visual acuity (BCVA) and central subfoveal thickness (CSFT) were measured at baseline and at 4, 8, and 12 weeks.

Results: Both groups demonstrated significant improvements in BCVA and CSFT from baseline to 12 weeks. The Ranibizumab group showed a reduction in CSFT from 447.43 ± 61.87 µm to 314.00 ± 24.74 µm, and the Razumab® group from 449.47 ± 47.12 µm to 330.13 ± 27.17 µm (p >0.05). BCVA improved from 0.77 ± 0.10 to 0.32 ± 0.06 logMAR in the Ranibizumab group and from 0.78 ± 0.10 to 0.34 ± 0.06 logMAR in the Razumab® group (p >0.05).

Conclusion: The study confirms that Razumab® is non-inferior to Ranibizumab in terms of efficacy and safety for managing DME. Its cost-effectiveness makes it a suitable alternative, particularly in resource-limited settings without compromising safety or efficacy.

Keywords: diabetes macular edema; vascular endothelial growth factor; biosimilar; central subfoveal thickness